Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 24, 2019
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex's Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period
ARCHAMPS, France, June 24, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) announced today the final results of its Phase 2 trial of ...
June 24, 2019
BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder
JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company ...
June 24, 2019
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
BUFFALO, N.Y., June 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
June 24, 2019
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
WATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and ...
June 24, 2019
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), the manufacturer of BELBUCA® (buprenorphine buccal film), CIII, shared today how its ...
June 24, 2019
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103
PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering ...
June 24, 2019
electroCore Announces gammaCore(TM) Listing on the NHS Supply Chain Catalogue
LONDON, and BASKING RIDGE, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCoreTM, the company’s ...
June 24, 2019
Kiadis Pharma Announces Results Annual General Meeting
Amsterdam, The Netherlands, June 24, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, ...
June 24, 2019
Immutep to Host Key Opinion Leader Call
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
June 21, 2019
Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
NANTES, France, June 20, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that, after reviewing global study data, the Independent Data ...
June 21, 2019
Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA ...
June 21, 2019
Vermillion Adds Two Major Contracted Agreements for OVA1
AUSTIN, Texas, June 20, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioinformatics-based women’s health company focused on gynecologic disease, today announced it has further ...
June 21, 2019
Zealand Pharma introduces new website to support people living with short bowel syndrome
Copenhagen, June 21, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development ...
June 21, 2019
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-APOC3 for the ...
June 21, 2019
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
June 18, 2019
CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference
MONMOUTH JUNCTION, N.J., June 18, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in ...
June 18, 2019
iCAD to Participate in the JMP Securities Life Sciences Conference and Piper Jaffray Heartland Summit
NASHUA, N.H., June 18, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael ...
June 18, 2019
DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
CUPERTINO, Calif., June 18, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients ...
June 18, 2019
CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
NEWARK, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for ...
June 18, 2019
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that ...
Page 20 of 169